Baird lowered the firm’s price target on TransMedics (TMDX) to $150 from $200 and keeps an Outperform rating on the shares. The firm said while they were braced for less upside in Q3, the company’s miss came as a surprise. However, they still delivered +64% growth and reiterated the FY24 guide, noting challenges were more transient, and didn’t stem from share loss/OCS disposable pricing pressure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics reports Q3 EPS 12c, consensus 29c
- TransMedics backs FY24 revenue view $425M-$445M, consensus $444.36M
- TransMedics Group options imply 19.0% move in share price post-earnings
- TMDX Upcoming Earnings Report: What to Expect?
- Closing Bell Movers: Costco slips 1% as Q4 revenue misses estimates